Manipal Acunova
Bangalore · Founded 2004
About Manipal Acunova
Manipal Acunova Ltd. operates as a specialty contract research organization. It provides clinical development services, including project management, clinical development management, biostatistics, medical writing, bio-availability/bio equivalence, and central lab. The company provides bioavailability and bioequivalence services, including regulatory consultancy, volunteer screening, protocol development, pharmacokinetic analysis, adverse event reporting and emergency treatment, data management and statistical analysis, report writing and submission, and specimen storage and archival. It also offers clinical reference laboratory services comprising clinical testing lab for clinical trials, pharmacy company research testing, and patient testing services; and clinical trials and research services, including clinical operations, regulatory strategy and consulting, clinical monitoring, patient recruitment, and supply management services. The company's clinical management services include laboratory data management, SAS programming, ECG core labs, radiology and imaging, coding and dictionary management, pharmacovigilance, and PK/PD analysis. In addition, it provides site management services. The company offers research services for pharmaceutical, biotechnology, device, research, and diagnostic companies in Europe, North America, and Asia. Manipal Acunova Ltd. is based in Bangalore, India with additional offices in Frankfurt, the United Kingdom; Princeton, the United States; Mangalore and Manipal, India; and Moscow, Russia.
Company Facts
- Founded: 2004
- Legal name: Manipal Acunova Ltd.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $3.3M
- Last round: Series Unknown (Dec 2009)
- Website: acunovalife.com
- Phone: +91 080-6691-5700
Social Profiles
Canonical: https://fsome.com/organization/manipal-acunova-8382986 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.